Table 1.
Case # | Sample | Age (years) | Gender | Location | EXT mutation analysisa (type of mutation) | Cartilage cap thickness (mm) |
---|---|---|---|---|---|---|
L-741 | GP | 2 | M | Femur | – | – |
L-996 | GP | 8 | M | Femur | – | – |
L-1142 | GP | 12 | F | Tibia | – | – |
L-1234 | GP | 8 | F | Femur | – | – |
L-298 | OC | 24 | M | Femur | EXT1 exon 3: c.1121 G > A, p.W374X (ns)b | 6 |
L-317 | OC | 31 | M | Tibia | None in EXT1 or EXT2 b | 4 |
L-332 | OC | 25 | M | Femur | None in EXT1 or EXT2 b | 5.5 |
L-523 | OC | 20 | M | Tibia | EXT1 del codon 235–239 (del Pro-Leu-Phe-Ser-Lys)b | 5 |
L-524 | OC | 26 | M | Tibia | EXT1 codon 164 GAC > CAC (Asp > His),exon 1: c.1212 G > C, p. D164Hb | 4.5 |
L-722 | OC | 15 | F | Radius | EXT2 IVS7 + 1 G > Ab | 1.5 |
L-726 | OC | 6 | M | Rib | EXT2 IVS7 + 1 G > A | 6 |
L-841 | OC | 14 | F | Femur | EXT2 deletion exon 6 + 7 (del)b | 8 |
L-1094 | OC | 6 | M | Femur | EXT2 del exon 6 + 7 | 3 |
L-1143 | OC | 39 | M | Femur | NA | 2 |
L-2029 | OC | 23 | F | Femur | EXT2 exon 7: IVS7 + 1 G > A | 3.5 |
L-2069 | OC | 11 | M | Tibia | EXT1 exon 1 c.538_539delAG, p.Ser180fsX7b | 5.5 |
L-2160 | OC | 48 | F | Scapula | EXT1 exon1 c.538_539delAG, p.Ser180fsX17 | 6 |
L-2350 | OC | 53 | F | Femur | EXT2 exon 7: IVS7 + 1 G > A | 1 |
L-951 | PCH | 24 | M | Fibula | NA | 8 |
L-2117 | PCH | 37 | M | Humerus | EXT1 exon 2: c.1056 + 1 G > A | 12 |
L-114 | PCH | 39 | M | Femur | EXT2 exon 5: 764 T > C, L255P (uv)b | 12 |
L-578 | PCH | 22 | F | Femur | EXT2 deletion exon 6 + 7 (del) | 11 |
L-2254 | PCH | 33 | F | Pelvis | EXT2 exon 6 c.980delG, p.Gly327AlafsX5 | 8 |
L-2372 | PCH | 54 | M | Rib | NA | 13 |
GP epiphyseal growth plate, OC osteochondroma, PCH low grade secondary peripheral chondrosarcoma, NA not analysed
aMutation nomenclature was according to the Nomenclature Working Group [30]; ns non-sense, del deletion, uv unclassified variant, fs frame shift, pm polymorphism